These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9600738)

  • 1. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9.
    Bronson RT; Donahue LR; Johnson KR; Tanner A; Lane PW; Faust JR
    Am J Med Genet; 1998 May; 77(4):289-97. PubMed ID: 9600738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation.
    Mirza M; Volz C; Karlstetter M; Langiu M; Somogyi A; Ruonala MO; Tamm ER; Jägle H; Langmann T
    PLoS One; 2013; 8(10):e75963. PubMed ID: 24124525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptotic photoreceptor loss and altered expression of lysosomal proteins in the nclf mouse model of neuronal ceroid lipofuscinosis.
    Bartsch U; Galliciotti G; Jofre GF; Jankowiak W; Hagel C; Braulke T
    Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6952-9. PubMed ID: 24084090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A metabolomic comparison of mouse models of the Neuronal Ceroid Lipofuscinoses.
    Salek RM; Pears MR; Cooper JD; Mitchison HM; Pearce DA; Mortishire-Smith RJ; Griffin JL
    J Biomol NMR; 2011 Apr; 49(3-4):175-84. PubMed ID: 21461951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease.
    Morgan JP; Magee H; Wong A; Nelson T; Koch B; Cooper JD; Weimer JM
    PLoS One; 2013; 8(11):e78694. PubMed ID: 24223841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct early molecular responses to mutations causing vLINCL and JNCL presage ATP synthase subunit C accumulation in cerebellar cells.
    Cao Y; Staropoli JF; Biswas S; Espinola JA; MacDonald ME; Lee JM; Cotman SL
    PLoS One; 2011 Feb; 6(2):e17118. PubMed ID: 21359198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal degeneration in motor neuron degeneration: a mouse model of ceroid lipofuscinosis.
    Chang B; Bronson RT; Hawes NL; Roderick TH; Peng C; Hageman GS; Heckenlively JR
    Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):1071-6. PubMed ID: 8125718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.
    Wheeler RB; Sharp JD; Schultz RA; Joslin JM; Williams RE; Mole SE
    Am J Hum Genet; 2002 Feb; 70(2):537-42. PubMed ID: 11727201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2.
    Benedict JW; Getty AL; Wishart TM; Gillingwater TH; Pearce DA
    J Neurosci Res; 2009 Jul; 87(9):2157-66. PubMed ID: 19235893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the autophagy-lysosome pathway is involved in neuropathology of the nclf mouse model of neuronal ceroid lipofuscinosis.
    Thelen M; Damme M; Schweizer M; Hagel C; Wong AM; Cooper JD; Braulke T; Galliciotti G
    PLoS One; 2012; 7(4):e35493. PubMed ID: 22536393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models.
    Sohar I; Sleat DE; Jadot M; Lobel P
    J Neurochem; 1999 Aug; 73(2):700-11. PubMed ID: 10428067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seizure susceptibility, phenotype, and resultant growth delay in the nclf and mnd mouse models of neuronal ceroid lipofuscinoses.
    Kriscenski-Perry E; Kovács AD; Pearce DA
    J Child Neurol; 2013 Sep; 28(9):1137-41. PubMed ID: 23838029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin-like growth factor-1 treatment.
    Cooper JD; Messer A; Feng AK; Chua-Couzens J; Mobley WC
    J Neurosci; 1999 Apr; 19(7):2556-67. PubMed ID: 10087069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuronal ceroid lipofuscinosis. Closing chapter of a long story].
    Elleder M
    Cesk Patol; 2000 May; 36(2):43-59. PubMed ID: 10916928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two related proteolipids and dolichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis.
    Faust JR; Rodman JS; Daniel PF; Dice JF; Bronson RT
    J Biol Chem; 1994 Apr; 269(13):10150-5. PubMed ID: 8144516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of the neuronal ceroid lipofuscinoses.
    Mole S; Gardiner M
    Epilepsia; 1999; 40 Suppl 3():29-32. PubMed ID: 10446748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis.
    Guarneri R; Russo D; Cascio C; D'Agostino S; Galizzi G; Bigini P; Mennini T; Guarneri P
    Brain Res; 2004 Jul; 1014(1-2):209-20. PubMed ID: 15213005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage analysis of late-infantile neuronal ceroid-lipofuscinosis.
    Sharp J; Savukoski M; Wheeler RB; Harris J; Järvelä I; Peltonen L; Gardiner M; Williams R
    Am J Med Genet; 1995 Jun; 57(2):348-9. PubMed ID: 7668361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral assessment in mouse models of neuronal ceroid lipofuscinosis using a light-cued T-maze.
    Wendt KD; Lei B; Schachtman TR; Tullis GE; Ibe ME; Katz ML
    Behav Brain Res; 2005 Jun; 161(2):175-82. PubMed ID: 15885820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An altered secretome is an early marker of the pathogenesis of CLN6 Batten disease.
    Best HL; Clare AJ; McDonald KO; Wicky HE; Hughes SM
    J Neurochem; 2021 May; 157(3):764-780. PubMed ID: 33368303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.